OpenEvidence × Springer Nature
Springer Nature and OpenEvidence announced a subscription agreement to make Springer Nature's peer-reviewed medical and scientific content available within the OpenEvidence AI platform for clinicians. [81, 88] The deal, effective August 5, 2026, allows physicians to retrieve and cite the publisher's research at the point of care. [81] Financial terms of the agreement were not disclosed. [90]
The asset
A subscription agreement to integrate peer-reviewed scientific and medical content from Springer Nature's portfolio into the OpenEvidence AI-powered clinical decision support platform.
The record
- Seller status
- Going concern
- Sector
- Academic publishing
- Modalities
- text
What it means if you hold data
This deal highlights the growing market for licensing high-quality, peer-reviewed research for specialized, high-stakes AI applications like clinical decision support, moving beyond general large language model training. It demonstrates a partnership model focused on integrating content into specific professional workflows with an emphasis on attribution and trust.